Bellwether Hearing to Set the Tone for Low Testosterone Therapies; Maintaining FVE for Acrux
We maintain our AUD 0.40 per share fair value estimate for no-moat Acrux and reiterate our very high fair value uncertainty rating after the first bellwether trial over prescription medication used to treat low testosterone was declared a mistrial. At current levels, we see the shares as undervalued. Although rescheduled for September, the trial involving Abbvie is the first of nearly 6,000 lawsuits filed over testosterone replacement therapies and we believe it will set the direction for other ...Acrux is a pharmaceutical company engaged in the development and commercialization of specialty and generic transdermal and topical pharmaceuticals for global markets. Co.'s topical or transdermal pharmaceutical product portfolio can be segregated into two streams - generic pharmaceutical products and specialty pharmaceutical products.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.